Low-THC cannabis extract improves autism symptoms in trial
NTI164, a novel medicinal cannabis extract, improves core symptoms of autism spectrum disorder: Results from a double-blind, randomised, controlled trial (The Harmony study).
AI Summary
A double-blind, randomised, placebo-controlled Phase II/III clinical trial tested NTI164, a full-spectrum medicinal cannabis extract containing less than 0.3% THC, in children with Level II/III autism spectrum disorder (ASD). Participants received NTI164 or placebo for 8 weeks, with some later receiving NTI164 in an open-label phase. The abstract reports an excellent safety profile but does not provide numerical effect sizes or participant numbers.
Compared with placebo, NTI164 was associated with statistically significant improvements in overall clinical severity, adaptive functioning, social responsiveness, and affective symptoms. Caregivers also reported better family experiences and quality of life. These findings suggest that this low-THC cannabis product may warrant further study as a potential treatment for core and associated ASD symptoms, although the results do not establish that all cannabis productsโor THC generallyโwill have the same effects.
๐ก Key Findings
๐
Original Abstract
Related Research
Similar Studies
More THC research papers you might find interesting.
Small lab study finds cannabis affected simulated driving and confidence
A lab method measures 17 cannabinoids across five hemp product types
A single-center study finds varied care and no recurrence in follow-up
Explore More Research
Stay informed about the latest cannabis science.